Skip to main content
Frontiers in Aging Neuroscience logoLink to Frontiers in Aging Neuroscience
editorial
. 2014 Aug 28;6:206. doi: 10.3389/fnagi.2014.00206

Nutritional status, oxidative stress and dementia: the role of selenium in Alzheimer's disease

Jose R Santos 1,*, Auderlan M Gois 2, Deise M F Mendonça 2, Marco A M Freire 3,*
PMCID: PMC4147716  PMID: 25221506

The term dementia derives from the Latin demens (“de”: private, “mens”: mind, intelligence, judgment—“without a mind”). The American Psychiatric Association (APA) describes it as “any mental impairment, or global cognitive decline in a previously unimpaired person” and is characterized by a deterioration of cognitive, intellectual, emotional, and behavioral skills, severe enough to interfere with the daily life of its sufferers (APA, 1994). It may be elicited by pathologies related to aging, stroke and mechanical injury, or by recurrent use of alcohol and substance abuse, including smoking (DeKosky et al., 2010; Rojas et al., 2010; Brown and Thore, 2011; Rusanen et al., 2011).

Dementias are far more prevalent in the elderly, since only about 5% of all reported cases involve people under 65 years-old, the so-called “early onset dementias” (Fadil et al., 2009). In the United States of America, the prevalence of dementia in individuals aging 90 or over exceeds 37% (Plassman et al., 2007). According to estimates from the Alzheimer's Disease International (ADI), about 36 million people around the world are currently suffering from some sort of dementia and this number was predicted to be at least three times higher in 2050 (ADI, 2010). Approximately two-thirds of all people with dementia live in less developed regions, and these disorders are considered a major burden for health care and social systems in developing countries (Wimo et al., 2003).

Alzheimer's disease (AD) is the major senile dementia, defined as a degenerative, progressive, and irreversible disorder, characterized by a gradual loss of cognitive function and by behavioral disturbances. It most commonly afflicts individuals over 65 years old, accounting for more than half of every worldwide dementia cases (LoGiudice, 2002). AD progression can be ranked into three stages. At the early stage, the patient has difficulty in thinking clearly, presenting a concomitant decrease in performance in complex tasks. At the moderate stage, aphasia is evident—inefficiency in naming objects or to choose the right word to express an idea. In the severe stage, there are prominent changes in the sleep-wake cycle, psychotic symptoms, and in the abilities to walk, talk, and self-care (Herrera-Rivero et al., 2010). Individuals become strictly dependent of caregivers and their condition deteriorates when psychiatric symptoms or often disruptive behavioral changes develop, imposing greater burden to the caregivers. Death usually occurs 3–9 years after the onset of symptoms (Querfurth and LaFerla, 2010).

Currently there is no effective treatment to AD and its cause (or causes) remains to be defined, although factors such as family history, diet, lifestyle, genetics, and head injury have been suggested. Familial AD involves mutations in the amyloid precursor protein and presenilins 1 and 2 (Rogaev et al., 1995; El Kadmiri et al., 2013), which cause overproduction of the β-amyloid protein. Moreover, increased levels of cholesterol, hypertension, and diabetes are also involved in AD development (Bassil and Mollaei, 2012; Wirz et al., 2014). An interdependence between cholesterol metabolism, Apolipoprotein E genotype and β-amyloid metabolic pathway has been reported, with implications to the pathogenesis of AD (Evans et al., 2004). Clinical findings suggest a lower risk of AD in individuals using statins in order to reduce their cholesterol levels (Shepardson et al., 2011).

A common condition in AD patients is weight loss, due to malnourishment induced by poor diet during the progression of the disease and the gradual impotence of feeding appropriately. A healthy nutrition, based on the correct selection and amount of micronutrients, contributes to delaying the cognitive decline both during aging and in AD patients (Lee et al., 2009; Spaccavento et al., 2009; Hadziabdic et al., 2012). Specific foods and diets have been reported to lower the risk of AD (Steele et al., 2007). The Mediterranean diet is based on a dietary pattern of high consumption of plant foods (fruits, vegetables, cereals, and nuts), olive oil as the main source of fat, a moderate intake of fish, and a low consumption of red meat. It is thus rich in omega-3 fatty acids, antioxidants and vitamins, especially B, C, and E (Willett et al., 1995). Antioxidant species are particularly important to help maintain the proper function of the brain (Gomez-Pinilla, 2008; Polidori et al., 2009), and their regular intake reduces oxidative stress (Steele et al., 2007; Otaegui-Arrazola et al., 2014).

Oxidative stress is a major harmful factor during aging and pathological conditions (Finkel and Holbrook, 2000; Freire, 2012). It is involved in the onset and progression of several neurodegenerative disorders, such as multiple sclerosis (Clausen et al., 1988; Gilgun-Sherki et al., 2004), amyotrophic lateral sclerosis (Baillet et al., 2010; Dias et al., 2013), Batten's disease (Clausen et al., 1988), Parkinson's disease (Freire and Santos, 2010; Dias et al., 2013), and AD (Markesbery, 1997; Pratico, 2008; Zhao and Zhao, 2013). Oxidative stress results from an imbalance between the levels of reactive oxygen species (ROS) and endogenous antioxidant mechanisms (Nunomura, 2013; Padurariu et al., 2013), which causes structural and functional impairment of cells by degrading lipids, proteins, and nucleic acids (Reynolds et al., 2007), and ultimately results in cell death.

NADPH oxidase (NOX) is one of the major enzymes involved in the process of oxidative stress. Its overexpression is induced especially by microglial activation in the brain in both acute (Block et al., 2007) and chronic conditions (Wu et al., 2003). NOX seems to play a role in AD, especially by the action of NOX2, which is upregulated in the brain of AD patients (Shimohama et al., 2000; Zekry et al., 2003). NOX2 expression is induced by the presence of β-amyloid plaques that stimulate the activation of microglial NOX leading to superoxide production (Wilkinson et al., 2012), which in turn leads to mitochondrial disfunction (Guimaraes et al., 2009), cleavage of nucleic acids (Nunomura et al., 2012), and proteolysis (Esler and Wolfe, 2001). There is a direct relationship between the impairment of cognitive performance of AD patients and the increase of NOX activity (Ansari and Scheff, 2012).

Glutathione peroxidase (GSH-Px) is a free radical scavenger and a key-enzyme in the endogenous defensive mechanism against free radicals (Chen and Berry, 2003). Its main role is to protect cells from ROS by inactivating hydrogen peroxides and lipid hydroperoxides originated during oxidative metabolism (Arthur, 2000). Accordingly, the decrease of GSH-Px activity leads to tissue damage and cell death due to detrimental action of ROS in increased levels. GSH-Px mechanism of action is based on the redox ability of thiol groups of glutathione and the catalytic reduction of peroxides, either inorganic (hydrogen peroxide) or organic (lipid peroxides). Its functioning is selenium-dependent (Ceballos-Picot et al., 1996), and a low dietary intake of this element alters GSH-Px activity (Arthur, 2000).

Selenium (Se) is micronutrient important to the maintenance of human health, and acts on immune defense, thyroid gland and cardiovascular functions, and cancer prevention (Finley, 2003; Thomson et al., 2009; Joseph and Loscalzo, 2013). Its deficiency results in cardiomyopathy associated to Keshan disease in children (Loscalzo, 2014), a pathology especially observed in regions where the soil is Se-deficient. As stated above, Se acts as an antioxidant component, working in combination with GSH-Px. They protect lipids by catalyzing the reduction of hydrogen peroxide and phospholipid hydroperoxides generated in vivo by ROS (Gamble et al., 1997).

Se main natural sources are bread, cereals, seafood, cruciferous vegetables (mainly broccoli) (Finley, 2005; Finley et al., 2005), and especially Brazil nut (Thomson et al., 2008). In an interesting study, Thomson et al. (2008) showed that the insertion of two units of Brazil nuts daily for 12 weeks in the diet increases Se levels in the humans' organism and enhances GSH-Px activity. In an animal model of Parkinson's disease, the systemic administration of Se improved antioxidant activity, protecting dopaminergic cells from the deleterious effects of 6-hydroxydopamine (Zafar et al., 2003), reinforcing the notion of its action in the redox balance in the brain. Se also combines with amino acids to form small peptides called selenoproteins (Papp et al., 2010), which exert antioxidant activities as enzymes (Takemoto et al., 2010; Zhang et al., 2010) and help block ROS involved in cell collapse, as it is seen in AD (Filipcik et al., 2006).

The physiological actions of micronutrients can be enhanced by their association with vitamins, which also play a significant role in reducing oxidative stress in the brain (Morris et al., 1998; Heo et al., 2013; Dysken et al., 2014). In this context, two vitamins are particularly important: vitamin C (ascorbic acid), considered the most important soluble antioxidant, able to neutralize ROS before the initiation of lipid peroxidation (Heo et al., 2013); and vitamin E, an important liposoluble antioxidant that is beneficial particularly at the membrane level, protecting polyunsaturated fatty acids from peroxidation (Tewari et al., 2014). The ingestion of high-dose vitamins E and C supplements may lower the risk of AD (Li et al., 2012; Heo et al., 2013; Dysken et al., 2014).

The clear-cut effects of dietary intake on overall health is well-established (Vermeer et al., 2003), and evidence suggests that nutritional deficiency contributes to the development of neuropathological conditions (Gillman et al., 1995). In a recent meta-analysis, Li et al. (2012) concluded that clinical studies about dietary intake of vitamins E, C, and β-carotene point to a positive role of these elements in prevention and interventional treatment of AD. Regarding Se, studies in humans confirm its participation in the prevention and treatment of brain disorders, either isolated or in combination with other elements (Sanmartin et al., 2011). Smorgon et al. (2004) described a direct correlation between the reduced Se plasma concentration and the decline of cognitive function in AD patients when compared to healthy individuals. Such event can be related to the process of oxidative stress reported in AD. Accordingly, in a recent study Olde Rikkert et al. (2014) found lower levels of Se in the plasma of non-malnourished patients in the early stage of AD when compared to healthy controls, suggesting that differences in nutritional status are present in AD even in the absence of malnutrition (Smorgon et al., 2004; Cardoso et al., 2010; Vural et al., 2010; Olde Rikkert et al., 2014).

Nonetheless, despite the correlations between some nutrients and cognitive function, more research has yet to be realized about the likely wide-ranging impact of nutrition and its benefits to neurodegenerative diseases. Overall, a diet including minerals and vitamins, especially associated to physical activity, importantly contributes to the attenuation of oxidative stress in the brain (Ma, 2008; Morris, 2009; van Praag, 2009). In addition, it is important to remark that the improvement of general nutritional status should be preferably based on food sources instead of alternative supplementation practices, since the formers are more accessible, sustainable, and present lower risk of toxicity than the latters (Finley, 2005).

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

Marco A. M. Freire is supported by Associação Alberto Santos Dumont para Apoio a Pesquisa (AASDAP)—Brazil.

References

  1. ADI. (2010). World Alzheimer Report. The Global Economic Impact of Dementia. London: Alzheimer's Disease International; Available online at: http://www.alz.co.uk/research/files/WorldAlzheimerReport2010ExecutiveSummary.pdf [Google Scholar]
  2. Ansari M. A., Scheff S. W. (2012). NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic. Biol. Med. 51, 171–178 10.1016/j.freeradbiomed.2011.03.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arthur J. R. (2000). The glutathione peroxidases. Cell. Mol. Life Sci. 57, 1825–1835 10.1007/PL00000664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. APA. (1994). American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington, DC: American Psychiatric Association [Google Scholar]
  5. Baillet A., Chanteperdrix V., Trocme C., Casez P., Garrel C., Besson G. (2010). The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem. Res. 35, 1530–1537 10.1007/s11064-010-0212-5 [DOI] [PubMed] [Google Scholar]
  6. Bassil N., Mollaei C. (2012). Alzheimer's dementia: a brief review. J. Med. Liban. 60, 192–199 Available online at: http://lebanesemedicaljournal.org/articles/60-4/review2.pdf [PubMed] [Google Scholar]
  7. Block M. L., Zecca L., Hong J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69 10.1038/nrn2038 [DOI] [PubMed] [Google Scholar]
  8. Brown W. R., Thore C. R. (2011). Review: cerebral microvascular pathology in aging and neurodegeneration. Neuropathol. Appl. Neurobiol. 37, 56–74 10.1111/j.1365-2990.2010.01139.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cardoso B. R., Ong T. P., Jacob-Filho W., Jaluul O., Freitas M. I., Cozzolino S. M. (2010). Nutritional status of selenium in Alzheimer's disease patients. Br. J. Nutr. 103, 803–806 10.1017/S0007114509992832 [DOI] [PubMed] [Google Scholar]
  10. Ceballos-Picot I., Merad-Boudia M., Nicole A., Thevenin M., Hellier G., Legrain S., et al. (1996). Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type–place of the extracellular glutathione peroxidase. Free Radic. Biol. Med. 20, 579–587 10.1016/0891-5849(95)02058-6 [DOI] [PubMed] [Google Scholar]
  11. Chen J., Berry M. J. (2003). Selenium and selenoproteins in the brain and brain diseases. J. Neurochem. 86, 1–12 10.1046/j.1471-4159.2003.01854.x [DOI] [PubMed] [Google Scholar]
  12. Clausen J., Jensen G. E., Nielsen S. A. (1988). Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease. Biol. Trace Elem. Res. 15, 179–203 10.1007/BF02990136 [DOI] [PubMed] [Google Scholar]
  13. DeKosky S. T., Ikonomovic M. D., Gandy S. (2010). Traumatic brain injury - football, warfare, and long-term effects. N. Engl. J. Med. 363, 1293–1296 10.1056/NEJMp1007051 [DOI] [PubMed] [Google Scholar]
  14. Dias V., Junn E., Mouradian M. M. (2013). The role of oxidative stress in Parkinson's disease. J. Parkinsons Dis. 3, 461–491 10.3233/JPD-130230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dysken M. W., Sano M., Asthana S., Vertrees J. E., Pallaki M., Llorente M., et al. (2014). Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33–44 10.1001/jama.2013.282834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. El Kadmiri N., Hamzi K., El Moutawakil B., Slassi I., Nadifi S. (2013). Genetic aspects of Alzheimer's disease (Review). Pathol. Biol. 61, 228–238 10.1016/j.patbio.2013.04.001 [DOI] [PubMed] [Google Scholar]
  17. Esler W. P., Wolfe M. S. (2001). A portrait of Alzheimer secretases–new features and familiar faces. Science 293, 1449–1454 10.1126/science.1064638 [DOI] [PubMed] [Google Scholar]
  18. Evans R. M., Hui S., Perkins A., Lahiri D. K., Poirier J., Farlow M. R. (2004). Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62, 1869–1871 10.1212/01.WNL.0000125323.15458.3F [DOI] [PubMed] [Google Scholar]
  19. Fadil H., Borazanci A., Ait Ben Haddou E., Yahyaoui M., Korniychuk E., Jaffe S. L., et al. (2009). Early onset dementia. Int. Rev. Neurobiol. 84, 245–262 10.1016/S0074-7742(09)00413-9 [DOI] [PubMed] [Google Scholar]
  20. Filipcik P., Cente M., Ferencik M., Hulin I., Novak M. (2006). The role of oxidative stress in the pathogenesis of Alzheimer's disease. Bratisl. Lek. Listy 107, 384–394 Available online at: http://www.bmj.sk/2006/107910-08.pdf [PubMed] [Google Scholar]
  21. Finkel T., Holbrook N. J. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408, 239–247 10.1038/35041687 [DOI] [PubMed] [Google Scholar]
  22. Finley J. W. (2003). Reduction of cancer risk by consumption of selenium-enriched plants: enrichment of broccoli with selenium increases the anticarcinogenic properties of broccoli. J. Med. Food 6, 19–26 10.1089/109662003765184714 [DOI] [PubMed] [Google Scholar]
  23. Finley J. W. (2005). Selenium accumulation in plant foods. Nutr. Rev. 63, 196–202 10.1111/j.1753-4887.2005.tb00137.x [DOI] [PubMed] [Google Scholar]
  24. Finley J. W., Sigrid-Keck A., Robbins R. J., Hintze K. J. (2005). Selenium enrichment of broccoli: interactions between selenium and secondary plant compounds. J. Nutr. 135, 1236–1238 Available online at: http://jn.nutrition.org/content/135/5/1236.full.pdf+html [DOI] [PubMed] [Google Scholar]
  25. Freire M. A. M. (2012). Pathophysiology of neurodegeneration following traumatic brain injury. West Indian Med. J. 61, 751–755 10.7727/wimj.2012.003 [DOI] [PubMed] [Google Scholar]
  26. Freire M. A. M., Santos J. R. (2010). Parkinson's disease: general features, effects of levodopa treatment and future directions. Front. Neuroanat. 4:146 10.3389/fnana.2010.00146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gamble S. C., Wiseman A., Goldfarb P. S. (1997). Selenium-dependent glutathione peroxidase and other selenoproteins: their synthesis and biochemical roles. J. Chem. Tech. Biotechnol. 68, 123–134 [Google Scholar]
  28. Gilgun-Sherki Y., Melamed E., Offen D. (2004). The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251, 261–268 10.1007/s00415-004-0348-9 [DOI] [PubMed] [Google Scholar]
  29. Gillman M. W., Cupples L. A., Gagnon D., Posner B. M., Ellison R. C., Castelli W. P., et al. (1995). Protective effect of fruits and vegetables on development of stroke in men. JAMA 273, 1113–1117 10.1001/jama.1995.03520380049034 [DOI] [PubMed] [Google Scholar]
  30. Gomez-Pinilla F. (2008). Brain foods: the effects of nutrients on brain function. Nat. Rev. Neurosci. 9, 568–578 10.1038/nrn2421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Guimaraes J. S., Freire M. A. M., Lima R. R., Souza-Rodrigues R. D., Costa A. M., dos Santos C. D., et al. (2009). Mechanisms of secondary degeneration in the central nervous system during acute neural disorders and white matter damage. Rev. Neurol. 48, 304–310 Available online at: http://www.neurologia.com/pdf/Web/4806/bb060304_ENGLISH.pdf [PubMed] [Google Scholar]
  32. Hadziabdic M. O., Bozikov V., Pavic E., Romic Z. (2012). The antioxidative protecting role of the Mediterranean diet. Coll. Antropol. 36, 1427–1434 Available online at: hrcak.srce.hr/file/139871 [PubMed] [Google Scholar]
  33. Heo J. H., Hyon L., Lee K. M. (2013). The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention. Am. J. Alzheimers Dis. Other Demen. 28, 120–125 10.1177/1533317512473193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Herrera-Rivero M., Hernandez-Aguilar M. E., Manzo J., Aranda-Abreu G. E. (2010). Alzheimer's disease: immunity and diagnosis. Rev. Neurol. 51, 153–164 Available online at: http://www.neurologia.com/pdf/Web/5103/be030153.pdf [PubMed] [Google Scholar]
  35. Joseph J., Loscalzo J. (2013). Selenistasis: epistatic effects of selenium on cardiovascular phenotype. Nutrients 5, 340–358 10.3390/nu5020340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lee K. S., Cheong H. K., Kim E. A., Kim K. R., Oh B. H., Hong C. H. (2009). Nutritional risk and cognitive impairment in the elderly. Arch. Gerontol. Geriatr. 48, 95–99 10.1016/j.archger.2007.11.001 [DOI] [PubMed] [Google Scholar]
  37. Li F. J., Shen L., Ji H. F. (2012). Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis. J. Alzheimers. Dis. 31, 253–258 10.3233/JAD-2012-120349 [DOI] [PubMed] [Google Scholar]
  38. LoGiudice D. (2002). Dementia: an update to refresh your memory. Intern. Med. J. 32, 535–540 10.1046/j.1445-5994.2002.00294.x [DOI] [PubMed] [Google Scholar]
  39. Loscalzo J. (2014). Keshan disease, selenium deficiency, and the selenoproteome. N. Engl. J. Med. 370, 1756–1760 10.1056/NEJMcibr1402199 [DOI] [PubMed] [Google Scholar]
  40. Ma Q. (2008). Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci. Bull. 24, 265–270 10.1007/s12264-008-0402-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Markesbery W. R. (1997). Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134–147 10.1016/S0891-5849(96)00629-6 [DOI] [PubMed] [Google Scholar]
  42. Morris M. C. (2009). The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur. J. Neurol. 16Suppl. 1, 1–7 10.1111/j.1468-1331.2009.02735.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Morris M. C., Beckett L. A., Scherr P. A., Hebert L. E., Bennett D. A., Field T. S., et al. (1998). Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 121–126 10.1097/00002093-199809000-00001 [DOI] [PubMed] [Google Scholar]
  44. Nunomura A. (2013). Oxidative stress hypothesis for Alzheimer's disease and its potential therapeutic implications. Rinsho Shinkeigaku 53, 1043–1045 10.5692/clinicalneurol.53.1043 [DOI] [PubMed] [Google Scholar]
  45. Nunomura A., Moreira P. I., Castellani R. J., Lee H. G., Zhu X., Smith M. A., et al. (2012). Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox. Res. 22, 231–248 10.1007/s12640-012-9331-x [DOI] [PubMed] [Google Scholar]
  46. Olde Rikkert M. G., Verhey F. R., Sijben J. W., Bouwman F. H., Dautzenberg P. L., Lansink M., et al. (2014). Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. J. Alzheimers Dis. 41, 261–271 10.3233/JAD-131892 [DOI] [PubMed] [Google Scholar]
  47. Otaegui-Arrazola A., Amiano P., Elbusto A., Urdaneta E., Martinez-Lage P. (2014). Diet, cognition, and Alzheimer's disease: food for thought. Eur. J. Nutr. 53, 1–23 10.1007/s00394-013-0561-3 [DOI] [PubMed] [Google Scholar]
  48. Padurariu M., Ciobica A., Lefter R., Serban I. L., Stefanescu C., Chirita R. (2013). The oxidative stress hypothesis in Alzheimer's disease. Psychiatr. Danub. 25, 401–409 Available online at: http://www.hdbp.org/psychiatria_danubina/pdf/dnb_vol25_no4/dnb_vol25_no4_401.pdf [PubMed] [Google Scholar]
  49. Papp L. V., Holmgren A., Khanna K. K. (2010). Selenium and selenoproteins in health and disease. Antioxid. Redox Signal. 12, 793–795 10.1089/ars.2009.2973 [DOI] [PubMed] [Google Scholar]
  50. Plassman B. L., Langa K. M., Fisher G. G., Heeringa S. G., Weir D. R., Ofstedal M. B., et al. (2007). Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125–132 10.1159/000109998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Polidori M. C., Pratico D., Mangialasche F., Mariani E., Aust O., Anlasik T., et al. (2009). High fruit and vegetable intake is positively correlated with antioxidant status and cognitive performance in healthy subjects. J. Alzheimers Dis. 17, 921–927 10.3233/JAD-2009-1114 [DOI] [PubMed] [Google Scholar]
  52. Pratico D. (2008). Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 29, 609–615 10.1016/j.tips.2008.09.001 [DOI] [PubMed] [Google Scholar]
  53. Querfurth H. W., LaFerla F. M. (2010). Alzheimer's disease. N. Engl. J. Med. 362, 329–344 10.1056/NEJMra0909142 [DOI] [PubMed] [Google Scholar]
  54. Reynolds A., Laurie C., Mosley R. L., Gendelman H. E. (2007). Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 82, 297–325 10.1016/S0074-7742(07)82016-2 [DOI] [PubMed] [Google Scholar]
  55. Rogaev E. I., Sherrington R., Rogaeva E. A., Levesque G., Ikeda M., Liang Y., et al. (1995). Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775–778 10.1038/376775a0 [DOI] [PubMed] [Google Scholar]
  56. Rojas G., Serrano C., Dillon C., Bartoloni L., Iturry M., Allegri R. F. (2010). Use and abuse of drugs in cognitive impairment patients. Vertex 21, 18–23 Available online at: http://europepmc.org/abstract/med/20440408 [PubMed] [Google Scholar]
  57. Rusanen M., Kivipelto M., Quesenberry C. P., Jr., Zhou J., Whitmer R. A. (2011). Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch. Intern. Med. 171, 333–399 10.1001/archinternmed.2010.393 [DOI] [PubMed] [Google Scholar]
  58. Sanmartin C., Plano D., Font M., Palop J. A. (2011). Selenium and clinical trials: new therapeutic evidence for multiple diseases. Curr. Med. Chem. 18, 4635–4650 10.2174/092986711797379249 [DOI] [PubMed] [Google Scholar]
  59. Shepardson N. E., Shankar G. M., Selkoe D. J. (2011). Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68, 1239–1244 10.1001/archneurol.2011.203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., et al. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273, 5–9 10.1006/bbrc.2000.2897 [DOI] [PubMed] [Google Scholar]
  61. Smorgon C., Mari E., Atti A. R., Dalla Nora E., Zamboni P. F., Calzoni F., et al. (2004). Trace elements and cognitive impairment: an elderly cohort study. Arch. Gerontol. Geriatr. Suppl. 9, 393–402 10.1016/j.archger.2004.04.050 [DOI] [PubMed] [Google Scholar]
  62. Spaccavento S., Del Prete M., Craca A., Fiore P. (2009). Influence of nutritional status on cognitive, functional and neuropsychiatric deficits in Alzheimer's disease. Arch. Gerontol. Geriatr. 48, 356–360 10.1016/j.archger.2008.03.002 [DOI] [PubMed] [Google Scholar]
  63. Steele M., Stuchbury G., Munch G. (2007). The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp. Gerontol. 42, 28–36 10.1016/j.exger.2006.06.002 [DOI] [PubMed] [Google Scholar]
  64. Takemoto A. S., Berry M. J., Bellinger F. P. (2010). Role of selenoprotein P in Alzheimer's disease. Ethn. Dis. 20, S1-92-95 Available online at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917322/pdf/nihms-220630.pdf [PMC free article] [PubMed] [Google Scholar]
  65. Tewari A., Mahendru V., Sinha A., Bilotta F. (2014). Antioxidants: the new frontier for translational research in cerebroprotection. J. Anaesthesiol. Clin. Pharmacol. 30, 160–171 10.4103/0970-9185.130001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Thomson C. D., Campbell J. M., Miller J., Skeaff S. A., Livingstone V. (2009). Selenium and iodine supplementation: effect on thyroid function of older New Zealanders. Am. J. Clin. Nutr. 90, 1038–1046 10.3945/ajcn.2009.28190 [DOI] [PubMed] [Google Scholar]
  67. Thomson C. D., Chisholm A., McLachlan S. K., Campbell J. M. (2008). Brazil nuts: an effective way to improve selenium status. Am. J. Clin. Nutr. 87, 379–384 Available online at: http://ajcn.nutrition.org/content/87/2/379.full.pdf+html [DOI] [PubMed] [Google Scholar]
  68. van Praag H. (2009). Exercise and the brain: something to chew on. Trends Neurosci. 32, 283–290 10.1016/j.tins.2008.12.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Vermeer S. E., Prins N. D., den Heijer T., Hofman A., Koudstaal P. J., Breteler M. M. (2003). Silent brain infarcts and the risk of dementia and cognitive decline. N. Eng. J. Med. 348, 1215–1222 10.1056/NEJMoa022066 [DOI] [PubMed] [Google Scholar]
  70. Vural H., Demirin H., Kara Y., Eren I., Delibas N. (2010). Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J. Trace Elem. Med. Biol. 24, 169–173 10.1016/j.jtemb.2010.02.002 [DOI] [PubMed] [Google Scholar]
  71. Wilkinson B. L., Cramer P. E., Varvel N. H., Reed-Geaghan E., Jiang Q., Szabo A., et al. (2012). Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol. Aging 33, 197.e121–197.e 132 10.1016/j.neurobiolaging.2010.06.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Willett W. C., Sacks F., Trichopoulou A., Drescher G., Ferro-Luzzi A., Helsing E., et al. (1995). Mediterranean diet pyramid: a cultural model for healthy eating. Am. J. Clin. Nutr. 61, 1402S–1406S [DOI] [PubMed] [Google Scholar]
  73. Wimo A., Winblad B., Aguero-Torres H., von Strauss E. (2003). The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Dis. 17, 63–67 10.1097/00002093-200304000-00002 [DOI] [PubMed] [Google Scholar]
  74. Wirz K. T., Keitel S., Swaab D. F., Verhaagen J., Bossers K. (2014). Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase? J. Alzheimers Dis. 38, 719–740 10.3233/JAD-130920 [DOI] [PubMed] [Google Scholar]
  75. Wu D. C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 6145–6150 10.1073/pnas.0937239100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Zafar K. S., Siddiqui A., Sayeed I., Ahmad M., Salim S., Islam F. (2003). Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J. Neurochem. 84, 438–446 10.1046/j.1471-4159.2003.01531.x [DOI] [PubMed] [Google Scholar]
  77. Zekry D., Epperson T. K., Krause K. H. (2003). A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? IUBMB Life 55, 307–313 10.1080/1521654031000153049 [DOI] [PubMed] [Google Scholar]
  78. Zhang S., Rocourt C., Cheng W. H. (2010). Selenoproteins and the aging brain. Mech. Ageing Dev. 131, 253–260 10.1016/j.mad.2010.02.006 [DOI] [PubMed] [Google Scholar]
  79. Zhao Y., Zhao B. (2013). Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid. Med. Cell. Longev. 2013:316523 10.1155/2013/316523 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Aging Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES